<DOC>
	<DOCNO>NCT02200718</DOCNO>
	<brief_summary>A Phase I Study NeuroVax™ , Novel Therapeutic TCR Peptide Vaccine Pediatric Multiple Sclerosis demonstrate safety &amp; efficacy</brief_summary>
	<brief_title>A Study NeuroVax™ , Novel Therapeutic TCR Peptide Vaccine Pediatric Multiple Sclerosis</brief_title>
	<detailed_description>A Multi-Center Phase I Study NeuroVax™ , Novel Therapeutic TCR Peptide Vaccine Pediatric Multiple Sclerosis demonstrate safety &amp; efficacy 12 subject pediatric MS</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Ages Eligible Study : 5 Years 17 Years Genders Eligible Study : Both Accepts Healthy Volunteers : No Criteria Subject 5 17 year age , inclusive Clinically diagnose Pediatric MS Definite Pediatric MS revise McDonald criterion ( 2005 ) ( Appendix A ) , pediatric MS course Expanded Disability Status Scale ( EDSS ) &lt; = score 6.5 ( Appendix B ) Two documented clinical relapse MS precede 24 month OR one document clinical relapse MS precede 12 month prior screen Laboratory value within follow limit : Creatinine 1 . 5 x high normal Hemoglobin Subjects currently prescribe Campath Lemtrada</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Multiple Sclerosis Pediatric MS NeuroVax Vaccine Therapeutic</keyword>
</DOC>